What are the bone dose constraints for stereotactic body radiotherapy (SBRT) delivered in four fractions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bone Dose Constraints for 4-Fraction SBRT

For 4-fraction SBRT to bone metastases, the spinal cord maximum point dose (Dmax) should not exceed 23.0 Gy to maintain radiation myelopathy risk at 1-5%, while vertebral compression fracture risk ranges from 10-20% and is primarily influenced by total dose and fractionation schedule. 1

Spinal Cord Constraints

The most critical constraint for spine SBRT is spinal cord tolerance. For 4-fraction regimens specifically, the thecal sac/spinal cord Dmax should be limited to 23.0 Gy to keep the risk of radiation myelopathy between 1-5%. 1 This represents the most rigorous modeling of spinal cord tolerance data available for SBRT.

Key Spinal Cord Principles:

  • Pre-SBRT MRI is strongly recommended to precisely delineate the spinal cord 2
  • The frequency of radiation-induced myelopathy following spine SBRT remains low at <2% when constraints are respected 2
  • For reirradiation scenarios, additional factors become critical: cumulative thecal sac EQD2₂ Dmax should remain ≤70 Gy, with SBRT contribution ≤25 Gy EQD2₂ 1

Vertebral Body and Fracture Risk

Vertebral compression fracture (VCF) is the most clinically relevant toxicity after SBRT, occurring in 10-20% of cases. 2 This risk is directly influenced by prescribed dose and fractionation:

  • Single-fraction SBRT doses >20 Gy carry greater fracture risk compared to fractionated regimens 2
  • Fractionated SBRT (including 4-fraction schedules) has not been associated with higher VCF risk compared to conventional RT 2
  • Most VCFs rarely require invasive management 2

Critical Pre-Treatment Assessment:

If the Spinal Instability Neoplastic Score (SINS) exceeds 7, stabilizing intervention should be performed before RT to reduce secondary fracture risk. 2 This is a mandatory evaluation step that directly impacts morbidity.

Non-Spine Bone Constraints

For non-spine bone metastases treated with SBRT, the main complications are:

  • Rib fractures: 2.5%
  • Femur fractures: 1.9% 2

The evidence shows that 4-fraction regimens for non-spine sites typically use doses ranging from 24-50 Gy in 3-5 fractions, with local control around 90% and low toxicity rates. 3

Additional Toxicity Considerations

Acute pain flare occurs in up to 30% of patients after SBRT, similar to conventional 3D radiotherapy. 2 This is a common but self-limited toxicity that should be anticipated and managed with prophylactic dexamethasone.

Concurrent Systemic Therapy Warning:

Particular attention is required when SBRT is performed with concurrent systemic treatment due to potential radiosensitizing effects that may increase toxicity risk. 2

Practical 4-Fraction Dosing Context

While the question asks specifically about 4-fraction constraints, the recent ESTRO guidelines recommend high-dose SBRT regimens including schedules such as 1×20 Gy, 1×24 Gy, 2×12 Gy, 3×10 Gy, and 5×7 Gy. 2 The 4-fraction schedule is less commonly reported in the literature compared to 1,3, or 5-fraction regimens, but the spinal cord constraint of 23.0 Gy Dmax remains the definitive limit. 1

The key algorithmic approach:

  1. Assess spinal stability (SINS score) - if >7, surgical stabilization first
  2. Obtain pre-treatment MRI for cord delineation
  3. Limit spinal cord Dmax to 23.0 Gy for 4 fractions
  4. Accept 10-20% VCF risk, which is rarely clinically significant
  5. Consider prophylactic steroids for pain flare
  6. Adjust for concurrent systemic therapy radiosensitization

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.